Skip to main content
An official website of the United States government
Email

Blog Posts by NCI Director Dr. W. Kimryn Rathmell

In posts written for Cancer Currents Blog and NCI Bottom Line: A Blog about Grants and More, Dr. W. Kimryn Rathmell highlights her vision for NCI, meetings with and partnerships in the cancer community, strategic and scientific initiatives to advance cancer research and care, and funding and grants news.

 

  • Drawing of circular maze with a bag of money at its center

    NCI's Fiscal Year 2025 Interim Paylines Announced

    In this edition of the Bottom Line blog, NCI Director Dr. Kimryn Rathmell shares the interim grant funding policies that will be in place until FY25 funding is finalized.

  • An image of a female researcher in the lab with several students to her left and right.

    Growing the Cancer Research Pipeline by Expanding Opportunities

    Posted on August 29, 2024
    NCI Director Dr. Kimryn Rathmell and Division of Cancer Biology Director Dr. Dan Gallahan explain how the R15 grant program supports researchers at smaller institutions and encourages students to pursue careers in cancer research.

  • Middle-aged woman with cancer having a virtual appointment with doctor on the computer.

    Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait

    Posted on May 31, 2024
    Reshaping the cancer clinical trials infrastructure to overcome key bottlenecks will involve embracing technology and collaboration, and inviting innovation, explain NCI Director Dr. W. Kimryn Rathmell and NCI Special Advisor Dr. Shaalan Beg.

  • A man looks at data charts and graphs on a computer screen in an office.

    Fiscal Year 2024 Appropriation Brings Clarity and Difficult Choices

    Posted on April 4, 2024
    In this edition of the Bottom Line blog, NCI Director Dr. W. Kimryn Rathmell discusses NCI’s fiscal year 2024 appropriation from Congress, which increases the base budget, but also reflects the end of dedicated funding for the Cancer Moonshot. The budget allows NCI to prioritize funding for new grants—particularly to early-stage investigators, training mechanisms, and Cancer Centers—while limiting the impact on continuing grants.

Email